Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOREM: Neo-adjuvant Adaptive Master Trial for Localized Cancers
NCT07262489Phase 2Recruiting
- Sponsor
- Unicancer
- Start
- Jan 2026
- Primary completion
- Nov 2029
- Countries
- 1
01
Overview
Phase 2, single-arm trial in cancer, sponsored by Unicancer. Primary endpoints: Efficacy of novel treatment strategies at 7 years, Safety of novel treatment strategies at 7 years and 1 more. Started Jan 2026; status: recruiting.
02
Conditions
cancer
Beyond the preview
Go deeper on NCT07262489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07262489.